Sadeq Vallian1, Mandana Sedaghat, Isar Nassiri, Ali Frazmand. 1. Division of Genetics, Department of Biology, Faculty of Science, The University of Isfahan, Hezarjerib St., Isfahan, Islamic Republic of Iran. svallian@medinews.com
Abstract
INTRODUCTION: p16(INK4A) is a tumor suppressor encoding the Cdk inhibitor protein, which acts to repress Cdk4/6 and pRb phosphorylation. p16(INK4A) gene can be inactivated by a variety of events, including promoter hypermethylation. MATERIALS AND METHODS: To investigate the methylation status of the p16(INK4A) gene in Iranian patients with breast carcinoma, promoter methylation was studied by methylation-specific PCR (MSP) and restriction enzyme-related PCR (REP). In addition, p16(INK4A) promoter was analyzed by PCR-SSCP in order to detection of mutation and single nucleotide polymorphisms. RESULTS: Analysis of 70 patients by MPS and REP showed hypermethylation of p16(INK4A) promoter in 35.7% (25/70) and 40% (28/70) of samples, respectively. Comparison of the molecular data and pathological information of the samples suggested that p16(INK4A) gene might be inactivated at the early stages in breast cancer. CONCLUSION: Therefore, it could be suggested that hypermethylation of p16(INK4A) promoter is one of the epigenetic factors affecting the progress of sporadic breast carcinogenesis in Iranian patients.
INTRODUCTION:p16(INK4A) is a tumor suppressor encoding the Cdk inhibitor protein, which acts to repress Cdk4/6 and pRb phosphorylation. p16(INK4A) gene can be inactivated by a variety of events, including promoter hypermethylation. MATERIALS AND METHODS: To investigate the methylation status of the p16(INK4A) gene in Iranian patients with breast carcinoma, promoter methylation was studied by methylation-specific PCR (MSP) and restriction enzyme-related PCR (REP). In addition, p16(INK4A) promoter was analyzed by PCR-SSCP in order to detection of mutation and single nucleotide polymorphisms. RESULTS: Analysis of 70 patients by MPS and REP showed hypermethylation of p16(INK4A) promoter in 35.7% (25/70) and 40% (28/70) of samples, respectively. Comparison of the molecular data and pathological information of the samples suggested that p16(INK4A) gene might be inactivated at the early stages in breast cancer. CONCLUSION: Therefore, it could be suggested that hypermethylation of p16(INK4A) promoter is one of the epigenetic factors affecting the progress of sporadic breast carcinogenesis in Iranian patients.
Authors: Charles R Holst; Gerard J Nuovo; Manel Esteller; Karen Chew; Stephen B Baylin; James G Herman; Thea D Tlsty Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701
Authors: Karuppiah Kannan; Norman E Sharpless; Jin Xu; Ronan C O'Hagan; Marcus Bosenberg; Lynda Chin Journal: Proc Natl Acad Sci U S A Date: 2003-01-21 Impact factor: 11.205
Authors: J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin Journal: Cancer Res Date: 1995-10-15 Impact factor: 12.701
Authors: Seoung Wan Chae; Jin Hee Sohn; Dong-Hoon Kim; Yoon Jung Choi; Yong Lai Park; Kyungeun Kim; Young Hye Cho; Jung-Soo Pyo; Jun Ho Kim Journal: Yonsei Med J Date: 2011-05 Impact factor: 2.759
Authors: Adana A Llanos; Ramona G Dumitrescu; Theodore M Brasky; Zhenhua Liu; Joel B Mason; Catalin Marian; Kepher H Makambi; Scott L Spear; Bhaskar V S Kallakury; Jo L Freudenheim; Peter G Shields Journal: Carcinogenesis Date: 2014-10-24 Impact factor: 4.944
Authors: Donato F Romagnolo; Kevin D Daniels; Jonathan T Grunwald; Stephan A Ramos; Catherine R Propper; Ornella I Selmin Journal: Mol Nutr Food Res Date: 2016-06 Impact factor: 5.914